anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

221,701-221,760 of 319,975

filter-aware
11
Includes both a longitudinal line chart of IRAK4 reduction and a grouped bar chart with a summary table for cytokine inhibition.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
12
Includes PK/PD correlation, IRAK4 levels in PBMC, and skin lesion reduction data.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
13
The slide displays 12 bar charts representing log2(fold change) for specific genes across individual patients.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
14
Includes error bars representing standard error of the mean; data points are plotted over 42 days.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
15
The slide includes a disclaimer regarding the non-head-to-head nature of the comparison.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
16
Data includes error bars representing standard error of the mean (S.E. of Mean) or 80% confidence intervals.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
17
The slide includes a disclaimer regarding the non-head-to-head nature of the comparison.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
18
The slide highlights a favorable safety profile with no serious adverse events (SAEs) or drug-related infections.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
19
Focuses on partnership dynamics and clinical progress.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
20
Includes clinical trial identifiers and definitions of acronyms in the footer.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
21
The slide uses an abstract, scientific-looking background, likely representing molecular or biological structures.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
22
Includes a table of prevalence/incidence for various indications and a diagram of the JAK-STAT signaling pathway.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
23
The slide uses a dual-chart layout to correlate tumor volume reduction with PK/PD profiles.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
24
The slide uses a process flow diagram to illustrate the dose escalation (0.05 to 0.40 mg/kg) leading to MTD/RP2D expansion into four specific patient cohorts.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
25
The table displays adverse events occurring in 2 or more patients. Data includes patient counts and percentages for both 'All' and 'Related' adverse events.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
26
Includes a line chart showing plasma concentration over time and a table summarizing PK parameters (Cmax, AUClast, Vd, CL, t1/2).Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
27
Data presented as % change from C1D1 Predose. Includes time course line chart and dot plot for maximum degradation.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
28
Data from a clinical study of KT-333, showing biomarker response across different dose levels (DL1, DL2, DL3).Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
29
Includes ASH logo and specific clinical trial metrics (DL levels, AE types).Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
30
The slide uses a split-layout: left side for clinical data results, right side for strategic positioning.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
31
Kymera | Investor Presentation Deck | 41 slidesKymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
32
Includes a waterfall plot of cell line dependency and a biological process diagram showing the MDM2-p53 feedback loop.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
33
Includes three dose-response curves and a comparative table of clinical stage and potency metrics.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
34
Comparison of KT-253 vs DS-3032 (SMI) across protein levels and tumor volume over time.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
35
Includes a visual representation of the dose escalation study design and a detailed table of patient baseline characteristics.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
36
The slide combines a biological mechanism diagram with clinical trial data (table and line chart) to validate the drug's mechanism of action.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
37
Swimmer plot showing days on study for three patients, with corresponding CT scan imagery for one patient.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
38
Clinical trial safety reporting slide.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
39
The slide uses a split-layout to contrast technical mechanism/data (left) with strategic market opportunity (right).Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
40
Kymera | Investor Presentation Deck | 41 slidesKymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · Roadmap1 hit
41
Kymera | Investor Presentation Deck | 41 slidesKymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · Roadmap1 hit
01
Slide 1
Larimar Therapeutics | Investor Presentation Deck | 44 slidesLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations 1 hit
02
Larimar Therapeutics | Investor Presentation Deck | 44 slidesLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations 1 hit
03
The slide uses a list-based layout to present key company milestones and financial health.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Executive Summary1 hit
04
The slide uses a two-column layout to contrast the current Phase 2 trial status with the upcoming OLE trial status.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
05
The slide uses a timeline framework to demonstrate long-term IP protection.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
06
The slide uses a medical context to establish the severity of the condition and the unmet medical need.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
The slide uses clinical data to establish the biological rationale for the therapeutic approach.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
08
The slide uses a visual comparison of protein structures to explain the mechanism of action.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
09
Details the dosing schedule (13 days) and specific sampling days for buccal cells, skin, and platelets across three dose levels.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
10
The slide displays two dot plots with error bars representing median and 25th/75th percentiles for FXN concentration changes from baseline.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
11
The slide outlines the methodology for a clinical trial, specifically focusing on the 28-day treatment schedule and cohort details.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
12
Data represents median and 25th/75th percentiles. Baseline values provided in footnotes.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
13
The slide establishes a baseline for FXN levels in healthy individuals to contextualize the deficiency seen in Friedreich's Ataxia (FA) patients.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
14
The slide highlights high completion rates and manageable adverse events, specifically noting injection site reactions (ISRs) as the most common side effect.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
15
FACOMS: Friedreich's Ataxia Clinical Outcome Measures StudyLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
16
The slide outlines a clinical development roadmap with specific trial types and status updates.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
17
The slide highlights the unique 'Protein replacement' approach of Nomlabofusp compared to other modalities like Mitochondrial Oxidative Stress Modifiers, Gene Expression Regulators, Pathway Modifiers, and Gene Therapy.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
18
Larimar Therapeutics | Investor Presentation Deck | 44 slidesLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
19
The slide uses a list-based layout to present key company milestones and status.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
20
Larimar Therapeutics | Investor Presentation Deck | 44 slidesLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
21
Larimar Therapeutics | Investor Presentation Deck | 44 slidesLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
22
Larimar Therapeutics | Investor Presentation Deck | 44 slidesLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
23
The slide serves as a credibility-building asset by showcasing a partnership with a key non-profit organization in the rare disease space.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
24
Larimar Therapeutics | Investor Presentation Deck | 44 slidesLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
25
The slide outlines the clinical trial methodology for a drug candidate in Friedreich's Ataxia (FA) patients.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
26
The slide details the dosing schedule (13 days) and specific sampling days for buccal cells, skin, and platelets across three dose cohorts (25mg, 50mg, 100mg).Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
27
The charts display median values with 25th and 75th percentile error bars.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
28
The table displays n (%) for categorical variables and descriptive statistics (mean, SD, median, range) for age.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
29
MAD likely stands for Multiple Ascending Dose.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit